Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14546267 | 1.00 | PARP1 (0.32) | PARP1MEN1ALDH1A1KMT2ACYP2D6 | |
| SCHEMBL16000556 | 1.00 | PARP1 (0.32) | PARP1MEN1ALDH1A1KMT2ACYP2D6 | |
| SCHEMBL13233696 | 0.87 | ACE (0.38) | PARP1L3MBTL1 | |
| SCHEMBL16000536 | 0.87 | ACE (0.38) | PARP1L3MBTL1 | |
| SCHEMBL57300 | 0.87 | ACE (0.38) | PARP1L3MBTL1 | |
| SCHEMBL26723935 | 0.85 | PARP1 (0.36) | PARP1ALDH1A1 | |
| SCHEMBL16388299 | 0.85 | PARP1 (0.36) | PARP1ALDH1A1 | |
| SCHEMBL18205572 | 0.84 | MEN1 (0.34) | MEN1ALDH1A1KMT2A | |
| SCHEMBL5701892 | 0.82 | ACE (0.40) | — | |
| SCHEMBL5701910 | 0.82 | ACE (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11834447-B2 | Indole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| US-10005768-B2 | Carboxamide derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10000475-B2 | Triazine carboxamides as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20180134690-A1 | INDAZOLES AND USE THEREOF | PURDUE PHARMA LP (US) | 2018-05-17 | — | — | US | disclosed |
| US-9884865-B2 | Azaspiro[4.5] decane derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9834543-B2 | Indazoles and use thereof | PURDUE PHARMA L.P. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9745287-B2 | Pyrimidines and use thereof | PURDUE PHARMA L.P. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170210713-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2017-07-27 | — | — | US | disclosed |
| US-9359330-B2 | Substituted piperidines as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160031873-A1 | Carboxamide Derivatives and Use Thereof | PURDUE PHARMA L.P. | 2016-02-04 | — | — | US | disclosed |
| US-20160009659-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2016-01-14 | — | — | US | disclosed |
| US-20150353512-A1 | TRIAZINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2015-12-10 | — | — | US | disclosed |
| US-20150284383-A1 | INDOLE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2015-10-08 | — | — | US | disclosed |
| US-9120786-B2 | Triazine carboxamides as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20150175569-A1 | DIBENZAZEPINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2015-06-25 | — | — | US | disclosed |
| US-20150057300-A1 | SUBSTITUTED PIPERIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2015-02-26 | — | — | US | disclosed |
| US-20140249128-A1 | TRIAZINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-09-04 | — | — | US | disclosed |
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | PARP1 1957/4885MEN1 3283/4885ALDH1A1 120/4885 |
| US-11834447-B2 | Indole derivatives and use thereof | TRPC4, TRPV4, TRPV1 | PARP1 3814/4885MEN1 1788/4885ALDH1A1 1024/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | PARP1 251/4885MEN1 1514/4885ALDH1A1 4236/4885 |
| US-20150175569-A1 | DIBENZAZEPINE DERIVATIVES AND USE THEREOF | CACNA1A, CACNA1D, CACNA1S | PARP1 3525/4885MEN1 1265/4885ALDH1A1 631/4885 |
| US-10005768-B2 | Carboxamide derivatives and use thereof | TRPV1, CACNA1A, SCN10A | PARP1 4392/4885MEN1 3470/4885ALDH1A1 1621/4885 |
| US-20160031873-A1 | Carboxamide Derivatives and Use Thereof | TRPV1, CACNA1A, SCN10A | PARP1 4392/4885MEN1 3687/4885ALDH1A1 1283/4885 |
| US-20140249128-A1 | TRIAZINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | TRPV1, SCN2A, SCN2B | PARP1 4474/4885MEN1 3264/4885ALDH1A1 790/4885 |
| US-20150353512-A1 | TRIAZINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | TRPV1, SCN2A, SCN2B | PARP1 4474/4885MEN1 3264/4885ALDH1A1 790/4885 |
| US-10000475-B2 | Triazine carboxamides as sodium channel blockers | TRPV1, SCN2A, SCN2B | PARP1 4474/4885MEN1 3264/4885ALDH1A1 790/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | PARP1 251/4885MEN1 1514/4885ALDH1A1 4236/4885 |
| US-20170210713-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | CACNA1A, TRPV1, TRPA1 | PARP1 4180/4885MEN1 3827/4885ALDH1A1 1063/4885 |
| US-20150284383-A1 | INDOLE DERIVATIVES AND USE THEREOF | TRPC4, TRPV4, TRPV1 | PARP1 3814/4885MEN1 1788/4885ALDH1A1 1024/4885 |
| US-20180134690-A1 | INDAZOLES AND USE THEREOF | TRPV3, TRPA1, TRPV1 | PARP1 4393/4885MEN1 2800/4885ALDH1A1 710/4885 |
| US-20160009659-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | CACNA1A, TRPV1, TRPA1 | PARP1 4159/4885MEN1 3846/4885ALDH1A1 989/4885 |
| US-20150057300-A1 | SUBSTITUTED PIPERIDINES AS SODIUM CHANNEL BLOCKERS | CACNA1A, SCN1B, CACNA1E | PARP1 3522/4885MEN1 2724/4885ALDH1A1 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.